In Mexico the Histopathological Registry of Malignant Neoplasms in 2002, reported 593 new cases of MM. Additionally the prognosis of patients with multiple myeloma is highly variable, with a median survival of 2-3 years. Daratumumab was recently approved as monotherapy for the treatment of Double Refractory Multiple Myeloma (DRMM) being the only drug approved in this indication to date in Mexico. OBJECTIVES:  To develop an economic analysis to estimate the budgetary impact of including Daratumumab in the public sector as a treatment for patients with DRMM. METHODS:  Currently in Mexico there’s no other drug approved for the treatment of DRMM patients therefore a budget impact analysis of the use of Daratumumab in different public institutions was carried out. Regarding the current alternative treatment, two therapeutic regimens were considered: thalidomide+dexamethasone representing 43% of targeted patients; and melphalan+prednisone for the rest of patients. The time horizon was 5 years and the costs were obtained from institutional sources. Finally a deterministic sensitivity analysis was performed to test uncertainty of main variables. RESULTS:  The estimate of DRMM patients in Mexico was 55 per year; hence the addition of daratumumab has a financial impact for the National Health System for the first year of 0.000629% of the budget, similar to budget impact in IMSS of 0.000408%, 0.000205% in ISSSTE, 0.002475% in Seguro Popular, 0.000043% in SEDENA, 0.000039% in SEMAR and 0.000006% in PEMEX. CONCLUSIONS:  There are currently no other therapeutic options approved for the treatment of DRMM patients, in addition to the few patients who are candidates for it the addition of daratumumab to public institutions in Mexico does not generate a high budgetary impact, while providing a targeted option of treatment for them.